Gentian Diagnostics (6FK) Stock Overview
Develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
6FK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 3.63 |
| 52 Week High | NOK 5.42 |
| 52 Week Low | NOK 3.27 |
| Beta | 0.32 |
| 1 Month Change | 8.68% |
| 3 Month Change | -25.46% |
| 1 Year Change | -2.42% |
| 3 Year Change | 7.72% |
| 5 Year Change | n/a |
| Change since IPO | -23.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 6.5% | 4.5% | 2.9% |
| 1Y | -2.4% | -15.2% | 12.1% |
Return vs Industry: 6FK exceeded the German Medical Equipment industry which returned -15.9% over the past year.
Return vs Market: 6FK underperformed the German Market which returned 11.4% over the past year.
Price Volatility
| 6FK volatility | |
|---|---|
| 6FK Average Weekly Movement | 10.4% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: 6FK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6FK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 64 | Matti Heinonen | www.gentian.com |
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. The company also develops faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency.
Gentian Diagnostics ASA Fundamentals Summary
| 6FK fundamental statistics | |
|---|---|
| Market cap | €58.59m |
| Earnings (TTM) | €1.19m |
| Revenue (TTM) | €15.82m |
Is 6FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FK income statement (TTM) | |
|---|---|
| Revenue | NOK 176.50m |
| Cost of Revenue | NOK 78.30m |
| Gross Profit | NOK 98.20m |
| Other Expenses | NOK 84.94m |
| Earnings | NOK 13.26m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 06, 2026
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 55.64% |
| Net Profit Margin | 7.51% |
| Debt/Equity Ratio | 0% |
How did 6FK perform over the long term?
See historical performance and comparisonDividends
Does 6FK pay a reliable dividends?
See 6FK dividend history and benchmarks| Gentian Diagnostics dividend dates | |
|---|---|
| Ex Dividend Date | May 06 2026 |
| Dividend Pay Date | May 18 2026 |
| Days until Ex dividend | 25 days |
| Days until Dividend pay date | 37 days |
Does 6FK pay a reliable dividends?
See 6FK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 05:53 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martinsson | DNB Carnegie |
| Geir Holom | DNB Carnegie |